66 related articles for article (PubMed ID: 11147250)
1. Drug therapy for hepatitis B.
Regev A; Schiff ER
Adv Intern Med; 2001; 46():107-35. PubMed ID: 11147250
[TBL] [Abstract][Full Text] [Related]
2. [New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
Petry W; Erhardt A; Heintges T; Häussinger D
Z Gastroenterol; 2000 Jan; 38(1):77-87. PubMed ID: 10689749
[TBL] [Abstract][Full Text] [Related]
3. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.
He Z; Wang J; Liu K; Huang H; Du Y; Lin Z; Cai M; Feng X
Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):592-7. PubMed ID: 23069315
[TBL] [Abstract][Full Text] [Related]
5. [The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
MMW Fortschr Med; 2003 Jun; 145(24):52. PubMed ID: 12866303
[No Abstract] [Full Text] [Related]
6. [New antiviral agent. Hepatitis B therapy with slight resistance risk].
MMW Fortschr Med; 2003 Dec; 145(51-52):40. PubMed ID: 14974332
[No Abstract] [Full Text] [Related]
7. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
8. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
[TBL] [Abstract][Full Text] [Related]
9. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
10. Advances in therapy for chronic hepatitis B.
Marcellin P
Semin Liver Dis; 2002; 22 Suppl 1():33-6. PubMed ID: 12447727
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant].
Kim JK; Hwang SG; Park H; Choi HY; Cho HJ; Ko KH; Hong SP; Park PW; Kim NK; Rim KS
Korean J Hepatol; 2005 Sep; 11(3):227-42. PubMed ID: 16177549
[TBL] [Abstract][Full Text] [Related]
12. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation.
Wang ZX; Ding GS; Fu H; Zhang JJ; Chen XS; Guo WY; Shi XM; Fu ZR
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):345-8. PubMed ID: 15313666
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study.
Limquiaco JL; Wong J; Wong VW; Wong GL; Tse CH; Chan HY; Kwan KY; Lai PB; Chan HL
J Med Virol; 2009 Feb; 81(2):224-9. PubMed ID: 19107976
[TBL] [Abstract][Full Text] [Related]
14. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
[TBL] [Abstract][Full Text] [Related]
15. Chronic hepatitis B--treatment with nucleoside analogues.
Leung N
Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
Ikeda F; Baba N; Takaguchi K; Kubota J; Miyoshi K; Fujioka S; Moritou Y; Takeuchi Y; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K
J Med Virol; 2012 Oct; 84(10):1562-70. PubMed ID: 22930504
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
[TBL] [Abstract][Full Text] [Related]
18. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
19. [Chronic hepatitis B. Recent advances in diagnosis and treatment].
Bernardi M; Biselli M; Gramenzi A
Recenti Prog Med; 2002; 93(7-8):397-402. PubMed ID: 12138683
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B.
Huang YW; Chayama K; Tsuge M; Takahashi S; Hatakeyama T; Abe H; Hu JT; Liu CJ; Lai MY; Chen DS; Yang SS; Kao JH
Antivir Ther; 2010; 15(2):177-84. PubMed ID: 20386072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
